Dendritic cells and interleukin 12 as adjuvants for tumor-specific vaccines

Adv Exp Med Biol. 1997:417:579-82. doi: 10.1007/978-1-4757-9966-8_93.

Authors

U Grohmann¹, R Bianchi, M L Belladonna, S Silla, D Surace, M C Fioretti, P Puccetti

Affiliation

¹ Department of Experimental Medicine, University of Perugia, Italy.

PMID: 9286421
DOI: 10.1007/978-1-4757-9966-8_93

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adjuvants, Immunologic / administration & dosage*
Animals
Antigens, Neoplasm
CD4-Positive T-Lymphocytes / immunology
Cancer Vaccines / administration & dosage*
Cell Differentiation
Dendritic Cells / immunology*
Histocompatibility Antigens Class I / metabolism
Immunotherapy / methods
Interleukin-12 / administration & dosage*
Mice
Neoplasms, Experimental / immunology
Neoplasms, Experimental / therapy
Th1 Cells / cytology
Th1 Cells / immunology

Substances

Adjuvants, Immunologic
Antigens, Neoplasm
Cancer Vaccines
Histocompatibility Antigens Class I
Interleukin-12